東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Chemotherapy for Leukemia = Novel Dr...

Ueda, Takanori.

FindBook

Google Book

Amazon

博客來

Chemotherapy for Leukemia = Novel Drugs and Treatment /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Chemotherapy for Leukemia/ edited by Takanori Ueda.
其他題名:	Novel Drugs and Treatment /
其他作者:	Ueda, Takanori.
出版者:	Singapore :Springer Singapore : : 2017.,
面頁冊數:	viii, 361 p. :ill., digital ;24 cm.
內容註:	1 An Overview -- Part I Bcr-Abl Tyrosine Kinase Inhibitors (TKIs) -- 2 Imatinib: Basic Results -- 3 Imatinib: Clinical Pharmacology and Therapeutic Results -- 4 Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs -- Part II New Antibodies for Leukemia -- 5 Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results -- 6 Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results -- 7 Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 8 Blinatumomab for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 9 Mogamulizumab in Adult T-cell Leukemia/Lymphoma -- Part III Signaling inhibitors -- 10. FLT3 inhibitors -- Part IV Differentiating Agents -- 11 Retinoic Acid, All-Trans Retinoic Acid (ATRA) and Tamibarotene -- 12 The Molecular Basis of Arsenic Trioxide Treatment for Acute Promyelocytic Leukemia (APL) -- 13 Arsenic Trioxide: Clinical Pharmacology and Therapeutic Results -- Part V New Chemotherapeutic Agents Including Antimetabolite -- 14 Nelarabine -- 15 Forodesine -- 16 Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology -- 17 Clinical Use of Clofarabine for Adults and Children with Leukemia -- 18 Re-Emerging Antimetabolites with Novel Mechanism of Action with Respect to Epigenetic Regulation: Basic Aspects -- 19 Epigenetic Regulator, Re-Emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results -- Part VI Therapy Targeting Leukemic Stem Cells -- 20 Therapies Targeting Leukemic Stem Cells.
Contained By:	Springer eBooks
標題:	Leukemia - Chemotherapy. -
電子資源:	http://dx.doi.org/10.1007/978-981-10-3332-2
ISBN:	9789811033322

Chemotherapy for Leukemia = Novel Drugs and Treatment /
Chemotherapy for LeukemiaNovel Drugs and Treatment /[electronic resource] :edited by Takanori Ueda. - Singapore :Springer Singapore :2017. - viii, 361 p. :ill., digital ;24 cm.

1 An Overview -- Part I Bcr-Abl Tyrosine Kinase Inhibitors (TKIs) -- 2 Imatinib: Basic Results -- 3 Imatinib: Clinical Pharmacology and Therapeutic Results -- 4 Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs -- Part II New Antibodies for Leukemia -- 5 Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results -- 6 Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results -- 7 Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 8 Blinatumomab for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 9 Mogamulizumab in Adult T-cell Leukemia/Lymphoma -- Part III Signaling inhibitors -- 10. FLT3 inhibitors -- Part IV Differentiating Agents -- 11 Retinoic Acid, All-Trans Retinoic Acid (ATRA) and Tamibarotene -- 12 The Molecular Basis of Arsenic Trioxide Treatment for Acute Promyelocytic Leukemia (APL) -- 13 Arsenic Trioxide: Clinical Pharmacology and Therapeutic Results -- Part V New Chemotherapeutic Agents Including Antimetabolite -- 14 Nelarabine -- 15 Forodesine -- 16 Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology -- 17 Clinical Use of Clofarabine for Adults and Children with Leukemia -- 18 Re-Emerging Antimetabolites with Novel Mechanism of Action with Respect to Epigenetic Regulation: Basic Aspects -- 19 Epigenetic Regulator, Re-Emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results -- Part VI Therapy Targeting Leukemic Stem Cells -- 20 Therapies Targeting Leukemic Stem Cells.

This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells. This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.

ISBN: 9789811033322

Standard No.: 10.1007/978-981-10-3332-2doiSubjects--Topical Terms:

3236848
Leukemia
--Chemotherapy.

LC Class. No.: RC643

Dewey Class. No.: 616.99419

Chemotherapy for Leukemia = Novel Drugs and Treatment /
LDR:03930nmm a2200313 a 4500 001 2097756
003 DE-He213
005 20170418083826.0
006 m d
007 cr nn 008maaau
008 171229s2017 si s 0 eng d
020 $a 9789811033322 $q (electronic bk.)
020 $a 9789811033308 $q (paper)
024 7 $a 10.1007/978-981-10-3332-2 $2 doi
035 $a 978-981-10-3332-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC643
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99419 $2 23
090 $a RC643 $b .C517 2017
245 0 0 $a Chemotherapy for Leukemia $h [electronic resource] : $b Novel Drugs and Treatment / $c edited by Takanori Ueda.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2017.
300 $a viii, 361 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1 An Overview -- Part I Bcr-Abl Tyrosine Kinase Inhibitors (TKIs) -- 2 Imatinib: Basic Results -- 3 Imatinib: Clinical Pharmacology and Therapeutic Results -- 4 Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs -- Part II New Antibodies for Leukemia -- 5 Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results -- 6 Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results -- 7 Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 8 Blinatumomab for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 9 Mogamulizumab in Adult T-cell Leukemia/Lymphoma -- Part III Signaling inhibitors -- 10. FLT3 inhibitors -- Part IV Differentiating Agents -- 11 Retinoic Acid, All-Trans Retinoic Acid (ATRA) and Tamibarotene -- 12 The Molecular Basis of Arsenic Trioxide Treatment for Acute Promyelocytic Leukemia (APL) -- 13 Arsenic Trioxide: Clinical Pharmacology and Therapeutic Results -- Part V New Chemotherapeutic Agents Including Antimetabolite -- 14 Nelarabine -- 15 Forodesine -- 16 Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology -- 17 Clinical Use of Clofarabine for Adults and Children with Leukemia -- 18 Re-Emerging Antimetabolites with Novel Mechanism of Action with Respect to Epigenetic Regulation: Basic Aspects -- 19 Epigenetic Regulator, Re-Emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results -- Part VI Therapy Targeting Leukemic Stem Cells -- 20 Therapies Targeting Leukemic Stem Cells.
520 $a This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells. This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.
650 0 $a Leukemia $x Chemotherapy. $3 3236848
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Oncology. $3 751006
650 2 4 $a Hematology. $3 808260
700 1 $a Ueda, Takanori. $3 3236847
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-981-10-3332-2
950 $a Medicine (Springer-11650)